AOND-21 is under clinical development by Aptarion Biotech and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect AOND-21’s likelihood of approval (LoA) and phase transition for Lung Adenocarcinoma took place on 14 Jan 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AOND-21 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
AOND-21 (formerly NOX-D21) is under development for the treatment of lung adenocarcinoma. The drug candidate acts by targeting complement component C5a. The drug candidate is based on the spiegelmers technology platform. Spiegelmers are mirror-image oligonucleotides either consisting of L-RNA or L-DNA building blocks or have the exact mirror-image behavior compared to natural nucleic acids. It was also under development for lung edema in bacterial pneumonia, septic shock, postoperative acute kidney injury and duchenne muscular dystrophy (DMD).
Aptarion Biotech overview
Quick View AOND-21 LOA Data
|Highest Development Stage|